Open house Pharmaceutical Discount Agreements Iron(III)-Derisomaltose, ATC B03AC08
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Eisen(III)-Derisomaltose, ATC B03AC08
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No estimated value or framework maximum is provided. The actual volume of business under these agreements is unknown, m...
Contracts automatically terminate if a national or regional discount agreement for the same active ingredient enters in...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jun 2027
- Conclusion of non-exclusive discount agreements (Rabattverträge) for the active ingredient Iron(III)-derisomaltose (ATC B03AC08) with AOK Bayern
- Agreements are identical for all participants, not individually negotiated
Show full summary
Open-house model for non-exclusive pharmaceutical discount agreements (Rabattverträge) for the active ingredient Iron(III)-derisomaltose (ATC B03AC08) offered by AOK Bayern. The procedure is not a public procurement but a voluntary open-house model open to all qualified pharmaceutical companies. Contracts run from 01.07.2025 to 30.06.2027, with possible termination if other discount agreements come into effect. No estimated value is provided.
Risks
No estimated value or framework maximum is provided. The actual volume of business under these agreements is unknown, m...
Contracts automatically terminate if a national or regional discount agreement for the same active ingredient enters in...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Signed contract including attachment 'Festlegung der vertragsgegenständlichen Arzneimittel'
Eligibility
- Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible
Administrative
- Submission of signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Pharmaceutical Discount Agreements Iron(III)-Derisomaltose, ATC B03AC08
Non-exclusive discount agreements for the active ingredient Iron(III)-derisomaltose for the region of Bavaria. Open to all pharmaceutical companies meeting eligibility criteria. Contracts can be concluded at any time until 05.05.2027, with start dates aligned to the first of the month after submission.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Eisen(III)-Derisomaltose, ATC B03AC08
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Procurement Details
- Publication date
- 15 May 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 316847-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No estimated value or framework maximum is provided. The actual volume of business under these agreements is unknown, m...
Contracts automatically terminate if a national or regional discount agreement for the same active ingredient enters in...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications